HRTX (STOCKS)
Heron Therapeutics, Inc.
$1.130000
-0.040000 (-3.42%)
Prev close: $1.170000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Craig A. Collard
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $209.95M
- Employees
- 122
- P/E (TTM)
- -14.22
- P/B (TTM)
- 30.54
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
6
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.04 | $-0.02 | -0.0247 | -161.44% |
|
Jun 2025 (Q2)
|
$-0.02 | $-0.01 | -0.0098 | -96.08% |
|
Mar 2025 (Q1)
|
$0.01 | $-0.01 | +0.0168 | +247.06% |
|
Dec 2024 (Q4)
|
$0.02 | $-0.03 | +0.0472 | +173.53% |
Financial Statements
| Revenues | $155.10M |
| Benefits Costs and Expenses | $127.98M |
| Cost Of Revenue | $40.46M |
| Costs And Expenses | $113.04M |
| Gross Profit | $114.64M |
| Operating Expenses | $113.04M |
| Research and Development | $11.86M |
| Other Operating Expenses | $101.18M |
| Operating Income/Loss | $1.60M |
| Income/Loss From Continuing Operations After Tax | -$13.58M |
| Income/Loss From Continuing Operations Before Tax | $52.44M |
| Net Income/Loss | -$13.58M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$13.58M |
| Net Income/Loss Available To Common Stockholders, Basic | -$13.58M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.08 |
| Diluted Earnings Per Share | -$0.09 |
| Basic Average Shares | 478,094,000 |
| Diluted Average Shares | 521,525,000 |
| Assets | $248.95M |
| Current Assets | $229.40M |
| Cash | $55.50M |
| Inventory | $70.03M |
| Other Current Assets | $103.88M |
| Noncurrent Assets | $19.55M |
| Fixed Assets | $12.96M |
| Other Non-current Assets | $6.59M |
| Liabilities | $234.07M |
| Current Liabilities | $89.71M |
| Accounts Payable | $12.02M |
| Wages | $8.75M |
| Other Current Liabilities | $68.94M |
| Noncurrent Liabilities | $144.36M |
| Equity | $14.89M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $14.89M |
| Liabilities And Equity | $248.95M |
| Net Cash Flow From Operating Activities | -$30.19M |
| Net Cash Flow From Operating Activities, Continuing | -$30.19M |
| Net Cash Flow From Investing Activities | $32.88M |
| Net Cash Flow From Investing Activities, Continuing | $32.88M |
| Net Cash Flow From Financing Activities | $14.63M |
| Net Cash Flow From Financing Activities, Continuing | $14.63M |
| Net Cash Flow | $17.33M |
| Net Cash Flow, Continuing | $17.33M |
| Comprehensive Income/Loss | -$13.62M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$13.62M |
| Other Comprehensive Income/Loss | -$13.62M |